Guggenheim 3rd Annual Healthcare Innovation Conference - ENTRADA THERAPEUTICS INC

Financial Performance:

• Revenue runway is secured through Q4 2027 with no inclusion of potential Vertex collaboration milestones in current cash projections.
• Vertex partnership included a $250 million upfront payment and potential milestones up to $485 million, though specific milestone values remain undisclosed due to contractual firewalls.
• Company has avoided significant equity dilution over four years as a public entity, positioning for future capital raises contingent on upcoming clinical data.

Guidance and Future Outlook:

• Expect four significant clinical readouts between current date and H1 2027:
  • Vertex DM1 (Exon 7) Phase 1 interim results before year-end.
  • DMD Exon 44 Cohort 1 (open label, 6 mg/kg) data before year-end.
  • DMD Exon 44 Cohort 2 (12 mg/kg) data in Q1 2027.
  • DMD Exon 45 Cohort 2 (10 mg/kg) data in H1 2027.
• Management anticipates a "hockey stick" dose-response for dystrophin expression in Exon 45 Cohort 2, potentially leading to a third cohort at 15 mg/kg.
• Long-term goal is global regulatory approval, leveraging US focus on dystrophin for accelerated approval and EU/XUS focus on functional benefit.

Business Segments and Product Lines:

• Platform: Utilizes Endosomal Escape Vehicles (EEVs), cyclic cell-penetrating peptides enabling intracellular delivery and early endosomal escape.
• Entero 44 (DMD): Targeting Exon 44 skipping; currently lowest dose at 6 mg/kg, with Cohort 2 at 12 mg/kg; aims to stabilize disease at minimal dystrophin levels.
• Entero 45 (DMD): Targeting Exon 45 skipping; dosing at 5 mg/kg in Cohort 1, 10 mg/kg in Cohort 2; designed for 1/6th the dose of competitor Casimersen (30 mg/kg) and administered every 6 weeks vs. weekly.
• Vertex Partnership (DM1): Preclinical asset now in Phase 1 for Myotonic Dystrophy Type 1; safety established with ongoing efficacy assessment.
• Differentiation: EEV platform allows smaller drug size (oligo + EEV) compared to competitors (e.g., 1/5th the size of Novartis/Vitriva drug; 1/6th dose of Sarepta), potentially reducing infusion-related side effects.

Market and Competitive Landscape:

• DMD Exon 44: Market faces high hurdles; competitor Novartis/Alnylam (Delzotar) struggled with dose response and patient dropouts; Entero aims to differentiate via safety and functional stability at lower doses.
• DMD Exon 45: No US therapeutic options outside of Casimersen/Amondus (approx. $300M sales); Entero offers significantly lower dosing frequency and amount.
• Market Trends: 90%+ of current exon skipping patients are home-administered weekly; Entero's 6-week dosing interval offers a major convenience advantage over standard weekly infusions.
• Competitive Safety: Entero reports zero patient dropouts due to safety across programs, contrasting with competitors experiencing infusion-related adverse events.

Risks and Challenges:

• Translational Risk: Challenges in translating non-human primate (NHP) models to human PK/PD profiles; initial Ann 45 safety data highlighted this hurdle.
• Regulatory Uncertainty: Correlation between dystrophin levels and functional benefit is emerging; US FDA requires statistically significant dystrophin for accelerated approval, while non-US agencies prioritize functional endpoints.
• Capital Requirements: Despite clean runway, future financing is necessary to sustain operations through data releases; timing of raises depends on positive clinical data to minimize dilution.
• Blindness: Strict firewall prevents immediate insight into Vertex DM1 efficacy data until public disclosure.

Management Commentary and Tone:

• Tone: Management (CEO Deepal Doshi) expressed cautious optimism, acknowledging the "unforgiving" market but highlighting the unique value proposition of the EEV platform.
• Confidence: High confidence in the platform's ability to target satellite cells (stem cells) for disease modification, potentially decoupling functional benefit from high dystrophin expression levels.
• Strategic Focus: Emphasis on "safety first" and "functional benefit," arguing that dosing convenience and low drug load are critical for patient quality of life and regulatory success.

Analyst Questions and Answers:

• Q: What is the expected dystrophin level for accelerated approval?
  • A: While exact thresholds are not guided, management expects a statistically significant change in dystrophin in Cohort 2 to satisfy US FDA requirements, while non-US agencies will prioritize functional data.
• Q: How does Entero differentiate from competitors on functional benefit?
  • A: Management believes Entero's ability to target satellite cells allows for functional benefits (e.g., time to rise) even at low dystrophin levels, whereas competitors like Novartis/Alnylam have struggled to demonstrate this.
• Q: Will patients switch from current therapies to Entero?
  • A: Patients prioritize functional ability and dosing convenience over dystrophin levels; Entero's 6-week dosing vs. weekly competitor infusions is a key driver for market adoption.
• Q: What functional metrics will be unveiled?
  • A: Includes NSAA, time to rise, power of 10-meter walk, and potential inclusion of 95C in expansion cohorts, despite 95C not being in the original protocol.

Other Key Points:

• Mechanism of Action: Hypothesis suggests the EEV platform delivers oligonucleotides to quiescent satellite cells for regeneration, in addition to reaching damaged muscle fibers.
• Safety Profile: No material renal effects observed, addressing a common liability in conventional DMD therapies; all treatment-emergent adverse effects (TEAEs) are manageable without study discontinuation.
• Dosing Strategy: Entero 45 program operates at significantly lower mg/kg compared to Sarepta, reducing total drug load per patient (e.g., 5 mg/kg vs. 30 mg/kg).